Research Updates

Back to feed
PubMed

High importance

Oct 31, 2026

Operating-room polidocanol sclerotherapy for HHT-related epistaxis.

View original source

Why it matters

The findings suggest that polidocanol sclerotherapy could be an effective and safe option for managing frequent nosebleeds in HHT patients, which can greatly affect their quality of life. Patients may want to discuss this option with their healthcare providers.

Objective

The study aimed to evaluate how well polidocanol sclerotherapy treats nosebleeds in people with Hereditary Hemorrhagic Telangiectasia (HHT).

Results

Patients experienced a significant decrease in nosebleeds, going from an average of 8.3 episodes per week to 2.35 episodes. About 85% of the patients saw at least a 50% reduction in their nosebleeds. Most patients felt positively about the treatment, with 95% willing to do it again.

Methods

The researchers looked at 20 adults who received this treatment in a hospital between March 2022 and December 2025. They reviewed information about how often patients had nosebleeds, any complications, and how satisfied patients were with the treatment.

Limitations

This study is based on a small group of patients and it's observational, meaning it didn't control for all variables. It also covers a retrospective review over a short time frame, so long-term effects are not yet known.

For your doctor:

PMID: 42966812

DOI: 10.1007/s00405-026-10780-1

Abstract

PURPOSE: Hereditary haemorrhagic telangiectasia (HHT) is frequently associated with recurrent epistaxis, causing morbidity and impaired quality of life. Data on operating room-based endonasal polidocanol sclerotherapy remain limited. This study aimed to assess the effectiveness, safety, patient acceptance, and procedural feasibility of this approach for HHT-related epistaxis. METHODS: A retrospective observational study was conducted in a tertiary referral centre including 20 adults with HHT treated with endonasal polidocanol sclerotherapy between March 2022 and December 2025. Clinical variables, visceral arteriovenous malformation (AVM) involvement, procedure-related variables, complications, and patient-reported outcomes were analysed. RESULTS: A total of 59 procedures were performed. Mean weekly epistaxis frequency decreased from 8.3 to 2.35 episodes per week (p < 0.001), with a mean relative reduction of 68.1% and an effect size of 1.27. Seventeen patients (85%) met responder criteria, defined as a reduction of at least 50% in weekly epistaxis frequency compared with baseline. Fourteen patients (70%) presented visceral AVM involvement, and 35% had high-burden disease. Severe epistaxis episodes requiring hospital-based care showed a non-significant numerical decrease. Two patients (10%) experienced complications, one requiring hospital admission. Nineteen patients (95%) reported willingness to undergo the procedure again. CONCLUSION: Operating room endonasal polidocanol sclerotherapy was associated with clinically meaningful reduction in epistaxis burden, high patient acceptance, and a favourable safety profile. This approach may represent a valuable option for selected patients with recurrent HHT-related epistaxis requiring structured management beyond an office-based setting.